Phase I clinical trial combining imatinib mesylate and IL-2-Reference-Cited by-同舟云学术

Phase I clinical trial combining imatinib mesylate and IL-2

Published:2013-02 Issue:2 Volume:2 Page:e23080
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Chaput Nathalie,Flament Caroline,Locher Clara,Desbois Mélanie,Rey Annie,Rusakiewicz Sylvie,Poirier-Colame Vichnou,Pautier Patricia,Le Cesne Axel,Soria Jean-Charles,Paci Angelo,Rosenzwajg Michelle,Klatzmann David,Eggermont Alexander,Robert Caroline,Zitvogel Laurence

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/onci.23080

Reference43 articles.

1. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2. The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2

3. A novel dendritic cell subset involved in tumor immunosurveillance

4. Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

5. Cyclophosphamide and cancer: golden anniversary

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers;Molecular Cancer;2023-04-18

2. The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals;Cancer Discovery;2022-02-18

3. The polarity and specificity of SARS-CoV2-specific T lymphocyte responses determine disease susceptibility;2021-06-22

4. HLA‐DR‐expressing NK cells: Effective killers suspected for antigen presentation;Journal of Leukocyte Biology;2020-05-18

5. Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis;Inflammopharmacology;2019-11-01